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Abstract
Background: Inhibition of the COP9 signalosome (CSN) associated kinases CK2 and PKD by
curcumin causes stabilization of the tumor suppressor p53. It has been shown that curcumin
induces tumor cell death and apoptosis. Curcumin and emodin block the CSN-directed c-Jun
signaling pathway, which results in diminished c-Jun steady state levels in HeLa cells. The aim of this
work was to search for new CSN kinase inhibitors analogue to curcumin and emodin by means of
an in silico screening method.
Methods: Here we present a novel method to identify efficient inhibitors of CSN-associated
kinases. Using curcumin and emodin as lead structures an in silico screening with our in-house
database containing more than 106 structures was carried out. Thirty-five compounds were
identified and further evaluated by the Lipinski's rule-of-five. Two groups of compounds can be
clearly discriminated according to their structures: the curcumin-group and the emodin-group. The
compounds were evaluated in in vitro kinase assays and in cell culture experiments.
Results: The data revealed 3 compounds of the curcumin-group (e.g. piceatannol) and 4 of the
emodin-group (e.g. anthrachinone) as potent inhibitors of CSN-associated kinases. Identified agents
increased p53 levels and induced apoptosis in tumor cells as determined by annexin V-FITC binding,
DNA fragmentation and caspase activity assays.
Conclusion: Our data demonstrate that the new in silico screening method is highly efficient for
identifying potential anti-tumor drugs.
Background
The COP9 signalosome (CSN), a conserved multimeric
protein complex, functions at the interface between signal
transduction and ubiquitin (Ub)-dependent proteolysis
[1]. Because of associated enzymes, the CSN possesses
kinase acitivity. Two of the associated kinases are the pro-
tein kinase CK2 (CK2) and the protein kinase D (PKD)
[2]. More than 200 proteins are known to be phosphor-
ylated by the CK2, which is located nearly everywhere in
the cell. The PKD is a serine/threonine kinase localized at
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either the plasma membrane or the cytosol of lym-
phocytes [3] and is associated with very diverse cellular
functions, including Golgi organization, plasma mem-
brane directed transport, metastasis, immune response,
apoptosis and cell proliferation [4]. It is assumed that the
CSN is a platform that brings together the kinases and
appropriate substrates [5]. Transcriptional regulators such
as p53 and c-Jun are phosphorylated by the CSN kinases
[6,7]. The phosphorylation of p53 at Thr155 results in
Ub-dependent degradation of the tumor suppressor [6].
In contrast, the CSN-directed phosphorylation of c-Jun
leads to the stabilization of the transcription factor
towards the Ub/26S proteasome system [8]. Cellular func-
tions such as regulation of transcription, DNA repair, cell
cycle regulation, senescence and apoptosis are modulated
by p53 as well as c-Jun. Defects most frequently observed
during tumorigenesis are mutations in the p53 gene [9]. It
is well known that wild type p53 provides a critical brake
in tumor development [10]. In contrast, as a component
of the activator protein-1 the onco-protein c-Jun is mostly
a positive regulator of cell proliferation and involved in
oncogenic transformation (for review see [11]). Hence,
the intracellular concentrations of p53 and c-Jun are deci-
sive for tumor development. Therefore, in tumor therapy
it is of great interest to control the stability of p53 and c-
Jun in tumor cells. One strategy might be the inhibition of
CSN-associated kinases, CK2 and PKD. It has been dem-
onstrated before that blocking CSN-mediated phosphor-
ylation causes an increase of p53 [6] and a decrease of c-
Jun [12], very useful effects for anti-tumor drugs. Curcu-
min has been identified as an inhibitor of CSN-associated
kinases [13], which is already in phase I clinical trials for
evaluations concerning the prevention of colon, breast,
lung and prostate cancer [14]. Former investigations
showed that curcumin is a potent inhibitor of angiogen-
esis [15] and of the recombinant kinases CK2, PKD and
the purified CSN complex from erythrocytes [2,13]. In
addition, a natural product called emodin is also known
as an inhibitor of the CK2 (PDB-Code: 1F0Q), PKD and
the CSN complex [2].
In this study we developed an in silico screening to identify
novel, more effective inhibitors of CSN-associated kinases
by using our in-house database (more than 106 com-
pounds). Curcumin and emodin served as lead structures
in the screenings. Using a 3D superposition algorithm
[16] the lead structures were compared with every com-
pound of the database. For better coverage of the com-
pounds and to assure their flexibility during usage of the
algorithm a total of ~50 conformers were computed for
every compound of the database. Compounds identified
from the in silico screening were evaluated in kinase assays
and cell culture experiments. With the new screening strat-
egy potential new drugs for tumor therapy were identified,
which stabilized endogenous p53 and induced apoptosis
in tumor cells.
Methods
In silico screening
Three dimensional (3D) similarity search
Lead structures (curcumin and emodin) and compounds
in the database were prepared for the 3D search, which is
based on structural similarities. As a first step the centers
of mass of each compound were determined and superim-
posed. The plane and the straight line of minimal quad-
ratic distance to all atoms were computed to determine
the least and largest (orthogonal) expansion. One struc-
ture was rotated such that the major directions coincide.
In a further step the normalization of the atomic set was
used to identify pairs of corresponding atoms. The root
mean square distance (rmsd) was calculated for the
related atomic pairs. An improvement of this value was
obtained by removing or adding atoms to this superposi-
tion [16].
Two dimensional (2D) similarity search
Another possibility to find new inhibitors of CSN-associ-
ated kinases was the 2D search, which is based on chemi-
cal similarities. The presence or absence of common
functional groups such as alcohols or ring systems such as
pyrimidins was investigated. Each substructure element
was assigned to one bit of a Boolean array. To calculate 2D
similarities between two structures the Tanimoto-coeffi-
cient was estimated. Bits set in both structures (BitsAB)
and bits, which were only set in one structure (BitsA and
BitsB) were taken into consideration. The value varies
between 0 (different molecules) and 1 (equal molecules):
[17].
In further steps each compound was analyzed for its pos-
sible application as a drug. First we investigated the
absorption and permeability using the Lipinski's rule-of-
five, which implies that molecules should contain less
than 10 H-bond-acceptors and less than 5 H-bond-
donors. The calculated logP-value (describes the
lipophilic properties) should be less than 5 and the
molecular weight should be less than 500 g/mol [18]. Any
compound violating more than one rule is not a promis-
ing candidate for a drug.
Based on the similar property principle one can predict
toxic effects from the molecular structure. We used two
quantitative structure toxicity relationship (QSTR) mod-
els to analyze the compounds for their toxicity. Using the
software TOPKAT® DS MedChem Explorer (Discovery Stu-
dio, Accelrys Inc., http://www.accelrys.com/dstudio/[19])
from Accelrys Inc., which comprises the QSTR models, the
toxicological data were obtained [20].
Tanimoto coefficient TC
BitsA BitsB BitsAB
−=
+−
()
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Kinase assay
Kinase activity was determined with [γ-32P]ATP (ICN) in a
buffer containing 30 mM Tris, pH 7.6, 10 mM KCl, 0.5
mM DTT. Full-length c-Jun was used as substrate. Recom-
binant CK2 (2α2β) and recombinant PKD were obtained
from Calbiochem and Upstate, respectively. The CSN was
isolated from human erythrocytes as outlined before [7].
The protein kinase inhibitors emodin and resveratrol were
purchased from Calbiochem, curcumin and piceatannol
were from Sigma. BTB00363 (2-Pyridinecarboxylic acid,
[(3,5-dichloro-2-hydroxyphenyl)methylene]hydrazide),
SEW04213 (6-fluoro-3,4-dihydro-2H-pyrano [2,3-b]qui-
nolin-5-amine), BTB14431 (9,10-dihydroxy-1,4-dihy-
droanthracene-1,4-dione), JFD02836 (3-methoxy-10-
methyl-9,10-dihydro-9-acridinone) and JFD03665 (10-
(hydroxymethylene)phenanthren-9(10H)-one) were
obtained from Maybridge. Approximately 1 µg of full-
length c-Jun was incubated with inhibitors at different
concentrations (0, 20, 50, 100 and 200 µM) and 10 µCi
[γ-32P]ATP for 60 min at 37°C. Reactions were stopped by
adding 3 µl of 4 × SDS-sample buffer (Roth). The samples
were separated by SDS-PAGE in a 12.5% gel, stained with
Coomassie, dried and exposed to X-ray film. Subsequently
the data were evaluated by densitometry. IC50 values
were calculated assuming Michaelis-Menten kinetics.
Cell culture
HeLa cells were cultured in RPMI 1640 medium contain-
ing 10% (v/v) fetal calf serum, 2 mM glutamine (Life
Technologies, Inc.), penicillin (100 U/ml) and streptomy-
cin (100 µg/ml) in a humidified 5% CO2 atmosphere. For
inhibitor treatment, 5–7 × 106 HeLa cells were incubated
with curcumin, resveratrol, piceatannol, BTB00363, emo-
din, SEW04213, BTB14431, JFD02836 or JFD03665 in
0.25% dimethyl sulfoxide (DMSO) for 4 h at indicated
concentrations. Control cells were treated with 0.25%
DMSO. After inhibitor treatment, cells were harvested and
lysed using ice-cold mono-detergent lysis buffer (50 mM
Tris pH 8.0, 1% Triton-X-100, 1 mM EDTA, 150 mM
NaCl, 1 µg/ml aprotinin, 1 µg/µl PMSF). HeLa cell lysate
proteins were separated by SDS-PAGE in a 12.5% gel,
blotted to nitrocellulose and probed with anti-c-Jun anti-
body (Calbiochem). For testing the intracellular concen-
tration of p53 by Western blot analysis, B8 cells (murine
fibroblasts) were cultured using Iscoves's MEM medium
(Biochrom) with 125 µg/ml G418 (Gibco BRL). Cells (5 ×
106 B8 cells/well) were incubated with resveratrol, picea-
tannol, emodin, BTB14431 or JFD02836 for 4 h at indi-
cated concentrations. Control cells were treated with
0.25% DMSO. After inhibitor treatment, cell lysates were
produced and analyzed as described for HeLa cells. Pro-
teins were probed with an anti-p53 antibody (IC Chemi-
kalien). All Western blots were developed using the ECL
technique (Amersham).
Caspase-3/7 activity assay
To determine apoptosis, B8 cells (104 cells/well) were
incubated with indicated inhibitors for 4 hours. After
incubation, the caspase-3/7 reagent, containing a DEVD-
peptide (Promega) was added as recommended by the
manufacturer (Promega). The fluorescence of each well
was measured at an excitation wavelength of 485 nm and
an emission wavelength of 530 nm.
Cell viability assay
Cell viability was assessed by the MTT [3-(4,5-dimethylth-
iazol-2-yl)-2,5-diphenyltetrazolium bromide] assay
(Sigma-Aldrich), which is based on the ability of a mito-
chondrial dehydrogenase from viable cells to oxidize the
tetrazolium rings of the pale yellow MTT and to form a
dark blue formazan crystals, which are largely impermea-
ble to cell membranes and, therefore, accumulate within
healthy cells. The number of surviving cells is directly pro-
portional to the concentration of the formazan produced.
Cells were incubated with the indicated inhibitors at dif-
ferent concentrations (20 or 50 µM) for 24 h. Then a solu-
tion of MTT in phosphate-buffered saline (PBS) was
added to each well to a final concentration of 0.5 µg/µl.
After 4 h incubation dark blue formazan was solubilized
with 100 µl DMSO. Absorbance was measured at 590 nm
using an ELISA reader.
Annexin-V-FITC/propidium iodide (PI) double staining
Annexin V binds to phosphatidyl serine externalized to
the outer leaflet of the plasma membrane bilayer during
initial stages of apoptosis. To measure cell staining by
annexin V the substance was labeled with FITC (fluores-
cein isothiocyanate). Simultaneously the cells were
stained with PI. By the double staining the test discrimi-
nates between intact (FITC-/PI-), apoptotic (FITC+/PI-)
and necrotic cells (FITC+/PI+) [21]. First, HeLa cells were
incubated with the indicated inhibitors at different con-
centrations (20 or 50 µM) for 24 h. After harvesting and
washing with PBS cells were resuspended in 100 µl
annexin V binding buffer (containing 10 mM HEPES/
NaOH, pH 7.4, 140 mM NaCl, 2.5 mM CaCl2). Subse-
quently cells were incubated with 5 µl of FITC-conjugated
annexin V (ApoTarget) for 20 min at room temperature.
After annexin-V-FITC staining, 400 µl of annexin V bind-
ing buffer containing PI (2.5 µg/ml) were added and the
cells were analyzed by flow cytometry within 1 hour after
staining.
DNA-fragmentation
Cells were seeded at a density of 105 cells/ml and treated
with different concentrations (20 and 50 µM) of the indi-
cated emodin- and curcumin-like compounds. After 24 h
the cells were collected, washed with PBS at 4°C and fixed
in PBS/2% (vol/vol) formaldehyde on ice for 30 min.BMC Cancer 2005, 5:97 http://www.biomedcentral.com/1471-2407/5/97
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Table 1: Creation of two groups of potential inhibitors of CSN-associated kinases. The structures found in the database by 3D and 2D 
screening were divided into two groups (curcumin-group and emodin-group) depending on the lead structures curcumin or emodin. 
The analysis of the 2D structures abet the division into the two groups. The double line marks the threshold, which normally limits the 
hits (2D similarity <85%).
Trade name 2D-structure 2D similarity (Tanimoto-coefficient)
Curcumin-group
Curcumin 1.0
Resveratrol 0.7
Piceatannol 0.7
BTB00363 0.7
Emodin-group
Emodin 1.0
BTB 14431 0.9
JFD02836 0.9
SEW 04213 0.8
JFD03665 0.8
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After fixation cells were incubated with ethanol/PBS (2:1,
vol/vol) for 15 min, pelleted and resuspended in PBS con-
taining 40 µg/ml RNase A. After incubation for 30 min at
37°C cells were pelleted again and finally resuspended in
PBS containing 50 µg/ml PI. The nuclear DNA fragmenta-
tion was then quantified by flow cytometric determina-
tion of hypodiploid DNA. Data were analyzed using the
CELLQuest software. Data are given in percentage of
hypoploidy (subG1), which reflects the number of apop-
totic cells.
Results
In silico screening plays an important role in drug-design
[21]. The method used here was developed to identify
potential new inhibitors of the CSN-associated kinases,
CK2 and PKD. Based on the structures of the known
3D superposition and 2D comparison of curcumin and piceatannol Figure 1
3D superposition and 2D comparison of curcumin and piceatannol. Comparison of curcumin and piceatannol struc-
tures by three-dimensional (3D) and two-dimensional (2D) superposition. A, The lead structure curcumin (blue) was aligned in 
a 3D superposition with the structure of piceatannol (green) obtained in the database. B, 2D similarities of curcumin and picea-
tannol are demonstrated. Both structures contain two aromatic rings and a large number of H-bond-acceptors. Using this 
information the Tanimoto-coefficient shown in Table 1 was calculated.BMC Cancer 2005, 5:97 http://www.biomedcentral.com/1471-2407/5/97
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In vitro kinase assays with piceatannol and BTB14431 Figure 2
In vitro kinase assays with piceatannol and BTB14431. Inhibition of CSN-associated kinases by curcumin- and emodin-
derived compounds in vitro. A, Piceatannol, identified by searching the database with curcumin as a lead compound and B, 
BTB14431, a compound found by searching the database with emodin. Recombinant CK2 and PKD as well as purified CSN 
were used to phosphorylate c-Jun in vitro. The first lane (0) is without inhibitors. Piceatannol (A) and BTB14431 (B) were added 
in increasing concentrations (20, 50, 100 and 200 µM). The shown autoradiographs were evaluated by densitometry. The 
obtained data were plotted against increasing inhibitor concentrations and used to calculate IC50 values summarized in Table 
2. The demonstrated results are representative for at least four independent experiments.BMC Cancer 2005, 5:97 http://www.biomedcentral.com/1471-2407/5/97
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inhibitors curcumin and emodin [2] a search in our in-
house database containing approximately 106  com-
pounds was performed. A 3D superposition algorithm
was developed to compare structures of the known inhib-
itors (lead structures) and the database compounds.
Using the 3D superposition algorithm the identification
of structures, which do not exactly fit into the pattern of
the lead structure (scaffold hoppers, 2D similarity <85%),
can be realized. To carry out specific searches, many fea-
tures such as the size of a molecule (Å), limit of rmsd,
number of assigned atoms and number of similar atoms
were compared. With this approach 35 compounds simi-
lar to the lead structures curcumin and emodin were iden-
tified and further analyzed.
As a first step we tested the behavior of the compounds
concerning the Lipinski's Rule-of-five using Accord for
Excel from Accelrys Inc. Our investigation showed that no
compound broke more than one rule (data not shown).
Further the toxicological effects of the compounds were
tested. Two QSTR models were employed: Rat Oral LD50
(Lethal Dose) and NTP (National Toxicology Program)
Rodent Carcinogenicity. All identified compounds were
predicted to be harmless.
Based on the different lead structures and the calculated
Tanimoto-coefficients the identified compounds were
divided into two groups (see Table 1). The compounds of
the first group were found by searching the database with
curcumin and the compounds of the second group are
related to emodin. Fig. 1A shows the superposition of the
structures curcumin (blue) and piceatannol (green). In
addition, the chemical properties of the two compounds
are compared (Fig. 1B). Both structures contain two aro-
matic rings and a number of H-bond acceptors, which
seem to be important for the inhibitory effect.
Effect of curcumin- and emodin-derived inhibitors on the stability of c-Jun and p53 Figure 3
Effect of curcumin- and emodin-derived inhibitors on the stability of c-Jun and p53. Curcumin- and emodin-derived 
inhibitors of CSN-associated kinases affect the stability of c-Jun and p53 in HeLa or B8 cells. HeLa cells or B8 cells were incu-
bated for 4 h with the inhibitors emodin, resveratrol, piceatannol, BTB14431 and JFD02836. The first lane is the control with-
out inhibitor. Proteins of cell lysates were separated by SDS-PAGE and transferred to nitrocellulose. The Western blots 
analysis was probed with an anti-c-Jun or an anti-p53 antibody.BMC Cancer 2005, 5:97 http://www.biomedcentral.com/1471-2407/5/97
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All 35 compounds selected from the database by the
screenings described above were tested in kinase assays for
their ability to inhibit CSN-associated kinases. In these
assays recombinant CK2 or PKD as well as purified CSN
were incubated in the presence of [γ-32P]ATP and 50 or
200 µM of the potential inhibitors (data not shown). The
data showed that only 7 out of 35 identified compounds
inhibited the CSN-associated kinases significantly in the
chosen concentration range. Therefore 7 reagents, 3 com-
pounds of the curcumin-group and 4 of the emodin-
group, were used for further analysis. Next IC50 values of
these 7 compounds were determined with recombinant
CK2, PKD or with the purified CSN. Kinase assays were
performed in the presence of different inhibitor concen-
trations. After incubation assays were analyzed by SDS-
PAGE and autoradiography. Kinase activity (%) was esti-
mated by densitometry. Fig. 2 demonstrates the results for
piceatannol (curcumin-group) and BTB14431 (emodin-
group). Values obtained by densitometry were plotted
against inhibitor concentrations. Obtained curves were
used to calculate IC50 values, which are summarized in
Table 1 for all tested compounds and compared with the
values for curcumin and emodin determined before [2].
Data show that curcumin-derived compounds seem to
have a higher affinity for PKD whereas inhibitors from the
emodin-group were more efficient in suppressing the
CK2. In most cases IC50 values obtained with the purified
CSN were lower than those with recombinant kinases
(Table 1).
Because cell treatment with curcumin or emodin led to
Ub- and proteasome-dependent degradation of c-Jun
[2,12], we tested whether HeLa cells incubated with differ-
ent concentrations of the new inhibitors possess
decreased c-Jun levels. It can be seen in the Western blot
analysis (Fig. 3A) that resveratrol as well as piceatannol
(curcumin-group) and BTB14431 as well as JFD02836
(emodin-group) induced a significant reduction of
endogenous c-Jun in a dose-dependent manner.
It has been shown before that curcumin stabilizes endog-
enous p53 toward the Ub system in HeLa and MCF7 cells
[6]. These cell lines possess wild type p53 [22-26]. We
were interested to see whether our new inhibitors of CSN-
associated kinases also increase intracellular steady state
p53 concentration. Mouse B8 fibroblasts, also expressing
wild type p53 [27] were treated with inhibitors. Subse-
quently cell lysates were tested by Western blot analysis
using an anti-p53 antibody. Data are shown in Fig. 3B. All
tested compounds induced significant stabilization of
endogenous p53 in B8 cells in a dose-dependent manner.
Interestingly, resveratrol at 200 µM was most effective in
stabilizing the tumor suppressor (Fig. 3B).
It has been shown that emodin, curcumin and resveratrol
induce apoptosis through p53-dependent pathways
[28,29]. Therefore we asked the question whether
piceatannol, BTB14431, SEW04213 and JFD02836 also
induce apoptosis. Several studies on compounds similar
to curcumin have been published. The ability to induce
apoptosis was measured in approximately 60 tumor cell
lines and effects were obtained in nearly all cells examined
[30]. Most studies demonstrate the execution of apoptosis
by the oxidation of tetrazolium [30], the measurement of
DNA-fragmentation as well as caspase activity and
annexin-V-FITC/propidium iodide (PI) double staining
[31]; methods also applied in our investigations.
First the caspase activity was measured in B8 fibroblasts.
Data shown in Fig. 4 demonstrate that all inhibitors tested
caused an increase of caspase activity. The most pro-
nounced increase was obtained with 50 µM of curcumin.
Piceatannol (50 µM) and BTB14431 (50 µM) elevated
caspase activity by approximately 5-times, whereas signif-
icant effects with SEW04213 and JFD02836 were only
obtained at compound concentrations of 200 µM.
Measurement of caspase activity after cell treatment with  curcumin- and emodin-derived inhibitors Figure 4
Measurement of caspase activity after cell treatment 
with curcumin- and emodin-derived inhibitors. Curcu-
min- and emodin-derived inhibitors of CSN-associated 
kinases induce apoptosis in B8 cells. Caspase-3/7 activities in 
mouse B8 fibroblasts were determined using a DEVD-pep-
tide. Cells (104/well) were treated with the inhibitors curcu-
min, piceatannol, BTB14431, SEW04213 and JFD02836 for 4 
h at 37°C. After incubating cells with caspase-3/7 reagent for 
3 h at room temperature the fluorescence (RFLU: relative 
fluorescent light units) was measured at an excitation wave-
length of 485 nm and an emission wavelength of 530 nm.BMC Cancer 2005, 5:97 http://www.biomedcentral.com/1471-2407/5/97
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To corroborate these findings we investigated the DNA-
fragmentation after treating HeLa cells with curcumin,
emodin, resveratrol, piceatannol, BTB14431 and
JFD02836 for 24 h. Except for JFD02836 in all experi-
ments apoptosis was triggered (Fig. 5B) and the subG1
peak, which reflects the number of apoptotic cells
increased in a dose-dependent manner (Fig. 5A).
In addition, by staining cells with annexin-V-FITC/PI cell
death was quantified [32]. After 24 h of incubation a large
number of apoptotic cells appeared in the experiments
with the inhibitors curcumin, piceatannol as well as
BTB14431 (Fig. 6B). Emodin and resveratrol produced
less apoptotic cells. In experiments with high
concentrations (50 µM) of curcumin and piceatannol
(Fig. 6A) increased amounts of necrotic cells were
observed.
The viability of the cells was checked by the MTT test,
which detects the percentage of irreversibly damaged cells
after treatment with the indicated inhibitors. By adding
curcumin and BTB14431 at a concentration of 20 µM the
percentage of viable cells decreased to ~25%. A significant
reduction of viable cells with emodin, resveratrol or picea-
tannol was only detected at high inhibitor concentrations
(50 µM) (Fig. 7).
Discussion and conclusion
Virtual screening versus high-throughput screening
Recently we have shown that curcumin and emodin,
inhibitors of CSN-associated kinases, induce Ub- and pro-
Detection of DNA-fragmentation in HeLa cells after 24 h incubation with kinase inhibitors Figure 5
Detection of DNA-fragmentation in HeLa cells after 24 h incubation with kinase inhibitors. Dose-dependent 
DNA-fragmentation in HeLa cells after 24 h treatment with curcumin- and emodin-derived inhibitors. (A) Representative data 
for piceatannol (20 µM and 50 µM) and BTB14431 (20 µM and 50 µM) are shown. As a control the cells were incubated with 
DMSO (0.1%). Piceatannol and BTB14431 were added in two concentrations (20 µM and 50 µM). The marker indicates the 
percentage of subG1 cells (apoptotic cells). (B) The bar chart shows the percentage of hypodiploid cells (apoptotic cells) after 
treatment with the inhibitors curcumin, emodin, resveratrol, piceatannol, BTB14431 or JFD02836 at different concentrations 
(20 µM and 50 µM).BMC Cancer 2005, 5:97 http://www.biomedcentral.com/1471-2407/5/97
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teasome-dependent degradation of c-Jun in tumor cells
[2,12]. Moreover, curcumin treatment causes stabilization
of the tumor suppressor p53 towards the Ub system [6]. It
has been demonstrated that curcumin- and emodin-
induced increase of p53 results in massive tumor cell
death due to p53-dependent apoptosis [28,29]. Therefore,
at least in tumor cells with wild type p53 elevation of cel-
lular p53 levels could be of high therapeutic effect. Both
events, the reduction of c-Jun and the increase of p53 are
important for tumor therapy and can be accomplished by
inhibition of CSN-associated kinases.
Therefore a new method was developed to identify com-
pounds which are effective blockers of CSN-associated
kinases and can be potentially used in tumor therapy. In
our in silico screening we referred to curcumin and emodin
as lead structures and compared them with approximately
106 compounds of our in-house database regarding their
structural properties (similar property principal). In con-
Apoptosis or necrosis: Annexin-V-FITC /PI double staining of HeLa cells after treatment with CSN kinase inhibitors Figure 6
Apoptosis or necrosis: Annexin-V-FITC /PI double staining of HeLa cells after treatment with CSN kinase 
inhibitors. HeLa cells were cultured in medium containing 0.1% DMSO or the curcumin- and emodin-derived inhibitors at dif-
ferent concentrations (20 µM and 50 µM). After 24 h cell death was measured at the single-cell level by labeling cells with 
annexin-V-FITC and counterstaining with propidium iodide (PI). (A) Representative data for piceatannol and BTB14431 are 
shown. The numbers indicate the percentage of cells in each quadrant (lower left: FITC-/PI-, intact cells; lower right: FITC+/PI-, 
apoptotic cells; upper left: FITC-/PI+, necrotic cells; upper right: FITC+/PI+, late apoptotic or necrotic cells). (B) The bar chart 
describes the percentual distribution of necrotic, apoptotic and viable cells after treatment with curcumin, emodin, resveratrol, 
piceatannol or BTB14431.BMC Cancer 2005, 5:97 http://www.biomedcentral.com/1471-2407/5/97
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trast to high-throughput screening (HTS) our method
allows to exclude a large number of compounds before
experimental testing. HTS is often used and appropriate
assay systems can evaluate more than 125,000 com-
pounds a day. However, HTS is not without problems
[33,34]. HTS experiments become more and more expen-
sive and the handling of the large amount of data is very
time consuming. In addition, it is difficult to exclude
false-positive hits [33]. By our virtual screening method
we identified 35 compounds that seemed to be promising
candidates for CSN kinase inhibition. Out of the 35 struc-
tures found by in silico screening 7 compounds had an
inhibitory effect on recombinant CK2 and PKD and on
the kinase activity of the purified CSN complex. Thus, the
hit rate of our virtual screening was 20%. In contrast, the
hit rate of HTS is usually approximately 2% [35]. We have
used additional methods such as the Lipinski rule-of five
and the toxicological investigations for ranking the found
substances. These methods, however, did not serve to
exclude compounds. Summing up, the data demonstrate
that our in silico screening is a reliable and efficient
method to find new active molecules.
The curcumin- and emodin-derived inhibitors of CSN-
associated kinases
The present study includes only compounds which were
identified using curcumin or emodin as lead structures.
Our screening revealed 3 compounds of the curcumin-
group and 4 compounds of the emodin-group, which
showed inhibition of the kinases in vitro and in cell exper-
iments. Interestingly, some of the identified compounds
are more effective inhibitors than the lead structure.
Therefore, in silico screening is a sensitive method for the
identification of molecules with specific biological
function. The two groups can be clearly divided by struc-
tural features. The different structures are most likely
responsible for their different effects. Whereas members
of the curcumin-group possess much better IC50 values
MTT test for detecting the cell viability after treatment with kinase inhibitors Figure 7
MTT test for detecting the cell viability after treatment with kinase inhibitors. The cells were treated with curcu-
min, emodin, resveratrol, piceatannol or BTB14431 for 24 h at different concentrations (20 µM and 50 µM). As a control the 
cells were cultured with 0.1% DMSO. The bar chart displays the amount of viable cells after treatment.BMC Cancer 2005, 5:97 http://www.biomedcentral.com/1471-2407/5/97
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with the PKD, the members of the emodin-group are
better inhibitors of CK2. However, all compounds inhibit
both CK2 and PKD relatively unspecifically. It has been
shown before that emodin is a competitive CK2 inhibitor
[36]. As demonstrated by crystal structure it binds into the
ATP-binding pocket of the kinase [37]. Simulation on the
basis of the emodin data revealed that curcumin also fits
into the same ATP-binding pocket of the CK2 (data not
shown). In addition, the effects of curcumin are reversible
[12] as it would be expected of a competitive inhibitor.
Therefore, we conclude that all identified compounds
compete with ATP for the ATP-binding site of the kinases.
Since the ATP-binding sites of CK2 and PKD are slightly
different, members of the curcumin-group have another
preference as compared to the emodin-group. On the
other hand, ATP-binding sites are highly conserved
among kinases. Therefore the identified kinase inhibitors
are rather unspecific.
Inhibitors of CSN-associated kinases are potential drugs 
for tumor therapy
Interestingly, many identified inhibitors of CSN-associ-
ated kinases are compounds of natural products such as
curcumin, resveratrol, piceatannol, emodin and
honokiol, which have been shown to inhibit angiogenesis
and development of malignancies [12,15,38,39]. Here we
demonstrate possible anti-tumor mechanisms of known
and new substances. The inhibitors of CSN-associated
kinases exhibit two important effects. As shown here they
reduce c-Jun levels in tumor cells. In addition, it has been
demonstrated that inhibitors of CSN-associated kinases
cause an increase of intracellular p53, which can be
explained by the stabilization of the tumor suppressor
towards the Ub/26S proteasome system [6]. However,
because our data were obtained by estimating steady state
levels of p53, altered expression might also contribute to
the increased protein concentration in the cells.
Nonetheless, elevated steady state levels of p53 are accom-
panied with massive cell death caused by apoptosis as
demonstrated here with B8 fibroblasts and HeLa cells. In
addition, the viability of the cells decreased after treat-
ment with the selected substances.
Based on our data we cannot exclude that the tested com-
pounds exert their pro-apoptotic effects independently of
the CSN and p53. For example, in addition to CSN-asso-
ciated kinases curcumin inhibits NF-κB activation associ-
ated with the induction of apoptosis [40]. Moreover,
although the exact role of c-Jun in apoptosis is not known,
low c-Jun steady state levels as measured in our experi-
ments also might contribute to the induction of the
apoptotic program (for rev. see [11]). In any case, the
identified inhibitors exert their effects by stimulating
apoptosis in tumor cells, which is most beneficial for
tumor therapy. Based on its anti-tumor potential the CSN
kinase inhibitor curcumin is already in phase I clinical tri-
als [14] and perhaps inhibitors identified here will follow.
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Table 2: Determination of IC50 values in an in vitro kinase assay. IC50 values (µM) for the inhibition of recombinant CK2, PKD and the 
purified CSN complex by the inhibitors of the curcumin-group, piceatannol as well as BTB00363, and of the emodin-group, BTB14431, 
JFD02836, SEW04213 and JFD03665 were determined. The two groups of inhibitors were created based on the different structures of 
the lead compounds (see Table 1). Kinase assays were performed as outlined in materials and methods. For comparison IC50 values of 
curcumin, resveratrol and emodin from earlier measurements [2] are shown.
Inhibitor IC50 CK2 (µM) IC50 PKD (µM) IC50 CSN (µM)
Curcumin-group
Curcurmin 11.8 4.1 2.6 *
Resveratrol 51.0 17.6 32.1 *
Piceatannol 2.5 0.5 1.7
BTB00363 332.7 117.7 188.6
Emodin-group
Emodin 22.7 94.5 4.4 *
BTB14431 6.4 68.9 21.0
JFD02836 19.9 39.7 54.1
SEW04213 37.9 185.9 4.8
JFD03665 5.9 154.9 19.8
* [2]BMC Cancer 2005, 5:97 http://www.biomedcentral.com/1471-2407/5/97
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